CD47 and neoplasm: In lung cancer, the CCL25/CCR9 axis promotes cancer progression [64,65,66], but intratumoral delivery of CCL25 attracts CCR9+ CD8+ T cells to infiltrate the tumor and enhances CD47-targeted immunotherapy in a murine TNBC model [64].